GlassScriptPhysician profile
Saly Arabo
NPI 1790123107
$3,353.24
in general payments reported to CMS, 2019-2025
30 companies · $525 in 2025
The $525 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,000 · 2022: $868 · 2023: $486 · 2024: $474 · 2025: $525.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,485.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,485.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $548.99 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $440.58 | 2021-2025 | Otezla, Repatha, Evenity |
| Ironwood Pharmaceuticals, INC | $342.71 | 2021-2023 | Linzess |
| Abbvie INC. | $300.52 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $248.43 | 2021-2025 | Ajovy, Austedo Xr |
| Lilly USA, LLC | $194.58 | 2021-2025 | Emgality, Reyvow, Kisunla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $171.52 | 2021-2024 | Jardiance, Spiriva Respimat |
| Novo Nordisk INC | $156.55 | 2021-2025 | Ozempic, Rybelsus |
| Sanofi-Aventis U.S. LLC | $89.18 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $85.22 | 2022 | |
| Janssen Pharmaceuticals, INC | $84.71 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $79.57 | 2021-2025 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $75.23 | 2022 | |
| Nestle Healthcare Nutrition INC. | $69.17 | 2021-2023 | |
| Dexcom, INC. | $63.28 | 2023-2024 | Dexcom G6 Transmitter |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $51.35 | 2021 | |
| Sumitomo Pharma America, INC. | $51.26 | 2025 | Gemtesa |
| Glaxosmithkline, LLC. | $45.90 | 2022-2025 | Trelegy Ellipta |
| Amarin Pharma, INC. | $42.12 | 2021-2022 | |
| Ardelyx, INC. | $38.20 | 2023-2024 | Ibsrela |
| Shield Therapeutics INC | $32.77 | 2023 | Accrufer |
| Exact Sciences Corporation | $28.34 | 2025 | Cologuard Collection Kit |
| Viatris Specialty LLC | $20.77 | 2025 | Yupelri |
| Merck Sharp & Dohme LLC | $15.57 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.87 | 2022 | |
| Aimmune Therapeutics, INC. | $14.49 | 2025 | Zenpep |
| Astellas Pharma US INC | $12.64 | 2022 | |
| Evoke Pharma, INC. | $11.88 | 2021 | |
| Hikma Pharmaceuticals USA | $11.42 | 2021 | |
| Eyevance Pharmaceuticals LLC | $11.42 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saly Arabo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.